Vitruvias Therapeutics, an Auburn, AL-based finished-dose generic drug company, has entered into a collaborative development agreement with a Hong Kong-based pharmaceutical company, Bright Future Pharmaceutical Lab to develop a portfolio of semi-solids to be marketed in the U.S. and China. U.S. distribution will be handled by Vitruvias and Bright Future will be responsible for China and other agreed upon Asian territories. The products will be manufactured by Bright Future’s newly constructed un...